AI-driven digital pathology raises the ceiling on consistency, accuracy, and reproducibility in biomarker analysis while simultaneously increasing the depth of data that can be generated at scale. Experience the next level of biomarker interpretation with Discovery’s advanced AI ecosystem.
Discovery continues to proactively build strategic partnerships with industry‑leading AI solution providers to realize AI’s potential, from RUO biospecimen annotation to regulated global clinical trials . By transforming images into quantitative, reproducible insights, our AI‑driven approach expands scale, boosts precision, and strengthens consistency across the entire research pipeline.
Since early 2025, Discovery has been proactively integrating AI across our workflows, leveraging decades of expertise in biospecimen solutions and specialty laboratory services.
Discovery’s AI pathology strategy pairs best-in-class technology with our deep clinical infrastructure — matching the right AI platform to each stage of your research and development program.
Discovery has deployed PathAI’s AISight® workflow solutions in our pathology workflow, enabling a new level of precision in tumor content quantification. AI-annotation is able to calculate tumor percent at a decimal-point level of precision, surpassing the traditional qualitative assessments of pathologists and empowering faster turnaround times for large-scale research projects.
ArtifactDetect automatically identifies potential histology and scanning QC issues.
TumorDetect identifies and quantifies cancer area, cancer stroma, and necrosis.
AISight® is for Research Use Only in the US; AISight® Dx is CE-IVD marked in the EEA, UK, and Switzerland. ArtifactDetect and TumorDetect are research use only products available on AISight® Image Management System, not for use in diagnostic procedures.
Watch to learn how we’re leveraging AI to increase accuracy on tasks humans can do (ex: tumor %), to increase the feasibility of tasks humans don’t do (ex: count cells), and to enable insights that humans genuinely can’t do (ex: discovery of novel predictive biomarkers)
DiscoverAI™, powered by PathAI, is the industry’s first joint offering that delivers quantitative characterization of the tumor microenvironment. It provides new insights through quantitative, human-interpretable features (HIFs) that define cell counts and densities by cell type and tumor region. As your entry point into a comprehensive suite, DiscoverAI™ enables hypothesis-driven analysis, uncovering spatial insights and relationships that are beyond human pattern recognition.
Inconsistent biomarker interpretation across pathologists is one of the more persistent challenges in clinical development — contributing to variability in patient stratification and eroding confidence in critical go/no-go decisions. Discovery’s partnership with Mindpeak addresses this head-on: combining AI-driven image analysis with rigorous pathology oversight to standardize interpretation, reduce variability, and give development teams the biomarker confidence they need to move forward decisively.
Automated quantification of IHC and mIF slides with subcelluar precision, improving consistency in biomarker interpretation across sites, readers, and geographies.
Mindpeak’s peakAcademy training platform, combined with Discovery’s Biomarker Academy – which has trained 6,000+ pathologists since 2008 – to standardize scoring across global trial teams.
Algorithms that isolate specific tissue regions with high accuracy, supporting cleaner, more reproducible data in complex multiplexed assays for regulated clinical studies.
Improving Pathology Precision in Oncology: How AI Reduces Variability in Tumor Percent Assignments Blog
AI-Powered Digital Pathology Solutions Brochure
Beyond Human Limits: Maximizing Biospecimen Value with Scalable, AI-Driven Tumor Analysis White Paper White Paper
